Union Bancaire Privee UBP SA Purchases 2,152 Shares of Amgen Inc. $AMGN

Union Bancaire Privee UBP SA lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 94.4% during the second quarter, Holdings Channel.com reports. The institutional investor owned 4,432 shares of the medical research company’s stock after acquiring an additional 2,152 shares during the quarter. Union Bancaire Privee UBP SA’s holdings in Amgen were worth $1,237,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in AMGN. Nuveen LLC bought a new position in shares of Amgen during the 1st quarter worth $688,868,000. Federated Hermes Inc. grew its position in shares of Amgen by 48.5% during the 1st quarter. Federated Hermes Inc. now owns 2,037,169 shares of the medical research company’s stock worth $634,680,000 after buying an additional 665,555 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Amgen by 128.9% during the 1st quarter. The Manufacturers Life Insurance Company now owns 1,065,694 shares of the medical research company’s stock worth $332,017,000 after buying an additional 600,096 shares in the last quarter. Kingstone Capital Partners Texas LLC bought a new position in shares of Amgen during the 2nd quarter worth $156,812,000. Finally, Assenagon Asset Management S.A. boosted its position in Amgen by 1,505.3% during the second quarter. Assenagon Asset Management S.A. now owns 518,604 shares of the medical research company’s stock valued at $144,799,000 after purchasing an additional 486,299 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the transaction, the senior vice president directly owned 7,209 shares in the company, valued at $2,141,000.91. This trade represents a 14.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 0.69% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on AMGN shares. Raymond James Financial started coverage on Amgen in a research report on Wednesday, September 3rd. They set a “market perform” rating on the stock. UBS Group dropped their price objective on Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $305.00 price objective on shares of Amgen in a research report on Tuesday, June 24th. Piper Sandler raised their price objective on Amgen from $328.00 to $342.00 and gave the company an “overweight” rating in a research report on Monday, August 25th. Finally, William Blair reaffirmed an “outperform” rating on shares of Amgen in a research report on Tuesday, June 24th. Seven equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Amgen currently has an average rating of “Hold” and a consensus price target of $309.70.

Amgen Trading Up 3.0%

Amgen stock opened at $282.20 on Wednesday. The stock has a 50-day moving average of $287.95 and a two-hundred day moving average of $288.57. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. Amgen Inc. has a one year low of $253.30 and a one year high of $335.88. The stock has a market cap of $151.93 billion, a PE ratio of 23.07, a price-to-earnings-growth ratio of 2.38 and a beta of 0.49.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, beating analysts’ consensus estimates of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The company had revenue of $9.18 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same period last year, the business posted $4.97 earnings per share. The firm’s revenue was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 12th. Stockholders of record on Friday, August 22nd were paid a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.4%. The ex-dividend date was Friday, August 22nd. Amgen’s dividend payout ratio (DPR) is presently 77.84%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.